SEC Tracker
Get the app

PAVmed PAVM

PAVmed raises $15M via Series C Preferred Stock

Item 1.01 Enters material agreement, Item 3.03 Changes shareholder rights

Form
8-K
Filed
Importance
Major
  1. Lucid Diagnostics, a PAVmed subsidiary, raised $15M
  2. 15,000 shares of Series C Preferred Stock sold at $1,000 per share
  3. Registration rights agreement filed for common stock resale

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when PAVmed files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Intelligent Bio Solutions INBS public float $12M, Dec 31, 2025
  2. PetVivo Holdings PETV public float $12M, Jun 29, 2026
  3. Lyra Therapeutics LYRA public float $11M, Jun 30, 2025
  4. Nexgel NXGL public float $11M, Jun 30, 2025
  5. Envoy Medical COCH public float $13M, Dec 31, 2025